Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKIs resistance via EGFR-independent signaling pathways.

Molecular cancer - 19 Feb 2018

Liu Qian, Yu Shengnan, Zhao Weiheng, Qin Shuang, Chu Qian, Wu Kongming

Abstract excerpt

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment. Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 29455669
DOI: 10.1186/s12943-018-0793-1
PMCID: PMC5817859

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-TKIs resistance via EGFR-independent signaling pathways.PMID 29455669Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

Mechanisms of resistance to EGFR tyrosine kinase inhibitorsSemantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.Semantic proximity Read ↗

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.Semantic proximity Read ↗

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic StrategiesSemantic proximity Read ↗

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.